SERNIVO® (betamethasone dipropionate) Spray, 0.05% is a corticosteroid indicated for the treatment of mild to moderate plaque psoriasis in people 18 years of age and older.2 IMPORTANT SAFETY INFORMATION2 Warnings and Precautions Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression and Other Unwanted Systemic Glucocorticoid Effects SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during or after withdrawal of treatment. Factors that predispose to HPA axis suppression include the use of high-potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age. Adverse Reactions The most common adverse reactions (> 1%) are application site reactions, including pruritis, burning and/or stinging, pain, and atrophy.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
